To investigate whether KRAS mutant deletion induces apoptosis in cancer cells, we assessed the percentage of apoptotic cells using flow cytometry with an Annexin V-AF488/propidium iodide (PI) double-staining assay.38 The assay was conducted on A549 cells treated with PEG-PLE/C14-PEI formulations at w/w ratios of 0.2 and 0.5, with C14-PEI, Lipofectamine 2000, and PEI used as controls. The gene discussed is KRAS; the disease is cancer.